Intralink-Spine (ILS) is a company formed to develop, manufacture, market, and sell a tissue modifying reagent that can be injected into the intervertebral disc of the human spine to increase crosslinking in the native collagen matrix.
ILS, a privately held medical device company focused on the treatment of degenerative disc disease and low back pain, announced today that it has been awarded a $750,000 Small Business Innovation Research (SBIR) Grant from the National Institutes of Health (NIH) for pre-clinical studies of its NEXT technology.
The NEXT device is designed to immediately strengthen and stabilize the disc, reducing disc bulge and pain without the costs and risks associated with surgery. Dr. Hansen Yuan, M.D., a leader in spine surgery, added: “This injectable tissue reinforcement procedure can provide an effective treatment for patients who are either early in the disease process or adverse to surgery.”
CNBC… http://ow.ly/12WsY
Website… http://www.intralink-spine.com